Cancer Research Technology
Log in Register
Menu
Search
Cell Lines

Cytarabine-resistant (1280nM) acute myeloid leukemia (AML) MOLM-13 cell line

Invented by Disha Malani , Olli Kallioniemi
Invented at University Of Helsinki
  • Datasheet
  • Inventor Info
Print

Info

Image thumbnail for Cytarabine-resistant (1280nM) acute myeloid leukemia (AML) MOLM-13 cell line
Add an image
Schematic diagram illustrating generation of cytarabine-resistant cell line variants. The MOLM-13 and SHI-1 cells were treated with escalating doses of cytarabine drug till the resistant cells grew at the equal proliferation rate of parental cells. The parental cells were cultured along with resistant cells to be used as controls to nullify possible effects of long-term cell vulture. All ten cell types were authenticated for authenticity and purity
Add an image
Image thumbnail for Cytarabine-resistant (1280nM) acute myeloid leukemia (AML) MOLM-13 cell line
Catalogue Number 159680
Antigen/Gene or Protein Targets Acute myeloid leukemia
Parental Line MOLM-13
Tissue Blood
Disease Keywords Cancer, acute myeloid leukemia, cytarabine-resistance, AML, chemotherapy resistance
Model Cancer Model
Relevance Acute myeloid leukaemia (AML) is a cancer of the myeloid line of blood cells, characterised by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Cytarabine is a common chemotherapy treatment for AML. Resistance to it in AML cells was shown to be linked to aberrant expression of equilibrative nucleoside transporters (ENT1) and metabolic enzymes deoxycytidine kinase (DCK) and cytosolic 5′-nucleotidase-II (NT5C2). The MOLM-13 cell line was derived from the peripheral blood of a patient at relapse of acute monocytic leukaemia.
Production Details This cell line and the others in this set were generated through long-term treatment of MOLM-13 cells with cytarabine. Doses were doubled when the AML cells started to proliferate at an equal rate as theuntreated parental cells.
Conditional No
Research Area Cancer
Growth/Phenotype Keywords cytarabine-resistant
Notes This cell line comes in a set of 4 cytarabine-resistant cell lines, with resistance to increasing doses of cytarabine. This cell line is resistant to 1240nM of cytarabine. The parental MOLM-13 cell line can be used as a negative control for cytarabine resistance.
Cytarabine resistance was found by the inventors of these cell lines to lead to glucocorticoid sensitivity as long as the cells had a wild- type fms like tyrosine kinase 3 (FLT-3) gene. This set of 4 MOLM-13 cells which have been made cytarabine resistant have a mutant form of FLT-3 (an an internal tandem duplication) and thus do not display glucocorticoid sensitivity. The related SHI-1 cell line which has similarly been made cytarabine resistant, contains the wild-type gene and thus is now sensitive to glucocorticoids. See Malani et al, Leukemia volume 31, pages1187–1195(2017) for details.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Malani et al. 2017. Leukemia. 31(5):1187-1195. PMID: 27833094.

View  

Add a reference

References: 1 entry

Malani et al. 2017. Leukemia. 31(5):1187-1195. PMID: 27833094.

View  

Add a reference

Inventor Information

Inventors

Disha Malani

Disha Malani

Olli Kallioniemi

Olli Kallioniemi

Add an inventor

Invented at

University Of Helsinki
University Of Helsinki

11 reagents listed on Ximbio